Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma

References

• FerlayJShinHRBrayFFormanDMathersCParkinDMEstimates of worldwide burden of cancer in 2008: GLOBOCAN 2008Int J Cancer2010127122893291721351269
   PubMed Web of Science ®Google Scholar
• WirthM PImmunotherapy for metastatic renal cell carcinomaUrol Clin North Am19932022832957684167
   PubMed Web of Science ®Google Scholar
• FyfeGFisherRIRosenbergSASznolMParkinsonDRLouieACResults of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapyJ Clin Oncol19951336886967884429
   PubMed Web of Science ®Google Scholar
• CliffordSCProwseAHAffaraNABuysCHMaherERInactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesisGenes Chromosomes Cancer19982232002099624531
   PubMed Web of Science ®Google Scholar
• LandSCTeeARHypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motifJ Biol Chem200728228205342054317502379
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTETomczakPOverall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinomaJ Clin Oncol200927223584359019487381
   PubMed Web of Science ®Google Scholar
• SternbergCNDavisIDMardiakJPazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trialJ Clin Oncol20102861061106820100962
   PubMed Web of Science ®Google Scholar
• HudesGCarducciMTomczakPGlobal ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinomaN Engl J Med2007356222271228117538086
   PubMed Web of Science ®Google Scholar
• EscudierBPluzanskaAKoralewskiPAVOREN Trial investigatorsBevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialLancet200737096052103211118156031
   PubMed Web of Science ®Google Scholar
• EscudierBBellmuntJNégrierSPhase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survivalJ Clin Oncol201028132144215020368553
   PubMed Web of Science ®Google Scholar
• RiniBIHalabiSRosenbergJEBevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with meta-static renal cell carcinoma: CALGB 90206J Clin Oncol200826335422542818936475
   PubMed Web of Science ®Google Scholar
• RiniBIHalabiSRosenbergJEPhase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206J Clin Oncol201028132137214320368558
   PubMed Web of Science ®Google Scholar
• EscudierBEisenTStadlerWMSorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trialJ Clin Oncol200927203312331819451442
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBOudardSRECORD-1 Study GroupEfficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialLancet2008372963744945618653228
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBOudardSRECORD-1 Study GroupPhase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factorsCancer2010116184256426520549832
   PubMed Web of Science ®Google Scholar
• CalvoEEscudierBMotzerRJEverolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 studyEur J Cancer201248333333922209391
   PubMed Web of Science ®Google Scholar
• ChoueiriTKAxitinib, a novel anti-angiogenic drug with promising activity in various solid tumorsCurr Opin Investig Drugs200896658671
   PubMed Web of Science ®Google Scholar
• KellyRJRixeOAxitinib – a selective inhibitor of the vascular endothelial growth factor (VEGF) receptorTarget Oncol20094429730519876699
   PubMed Web of Science ®Google Scholar
• Hu-LoweDDZouHYGrazziniMLNonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3Clin Cancer Res200814227272728319010843
   PubMed Web of Science ®Google Scholar
• RugoHSHerbstRSLiuGPhase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical resultsJ Clin Oncol200523245474548316027439
   PubMed Web of Science ®Google Scholar
• RiniBPhase 2 study of Axitinib in sorafenib-refractory metastatic renal cell carcinomaJ Clin Oncol2009274462446819652060
   PubMed Web of Science ®Google Scholar
• DutcherJPWildingGRHudesWMSequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib aloneJ Clin Oncol200826SupplAbstr 5127
   Google Scholar
• RixeOBukowskiRMMichaelsonMDAxitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II studyLancet Oncol200781197598417959415
   PubMed Web of Science ®Google Scholar
• MotzerRJde LaMotteRougeTHarzstarkALAxitinib second-line therapy for metastatic renal cell carcinoma (mRCC): five-year (yr) overall survival (OS) data from a phase II trialJ Clin Oncol201129SupplAbstr 4547
   Google Scholar
• RiniBIEscudierBTomczakPComparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialLancet201137898071931193922056247
   PubMed Web of Science ®Google Scholar
• PfizerAxitinib (AG-013736) with or without dose titration (increase) in patients with kidney cancerClinicalTrialsgov [website on the Internet]Bethseda, MDUS National Library of Medicine2009 [updated November 9, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT00835978NLM identifier: NCT00835978. Accessed November 23, 2012
   Google Scholar
• CellaDEscudierBRiniBIPatient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC)J Clin Oncol201129SupplAbstr 4504
   Web of Science ®Google Scholar
• PfizerAxitinib (AG-013736) for the treatment of metastatic renal cell cancerClinicalTrialsgov [website on the Internet]Bethseda, MDUS National Library of Medicine2009 [updated November 19, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT00920816NLM identifier: NCT00920816. Accessed November 23, 2012
   Google Scholar
• HutsonTEscudierBEstebanETemsirolimus vs Sorafenib as Second Line Therapy in Metastatic Renal Cell Carcinoma: Results From the INTORSECT TrialPresented at the 37th Congress of the European Society for Medical Oncology (ESMO)Vienna, AustriaSeptember 28–October 2, 2012 Abstract LBA22
   Google Scholar